Wave Life Sciences Ltd. (NASDAQ:WVE) Shares Purchased by Barclays PLC

Barclays PLC raised its holdings in Wave Life Sciences Ltd. (NASDAQ:WVE - Free Report) by 171.1% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 159,241 shares of the company's stock after acquiring an additional 100,498 shares during the quarter. Barclays PLC owned approximately 0.13% of Wave Life Sciences worth $1,307,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Orion Portfolio Solutions LLC bought a new position in shares of Wave Life Sciences in the third quarter worth about $123,000. XTX Topco Ltd bought a new stake in Wave Life Sciences during the 3rd quarter valued at about $126,000. Jane Street Group LLC boosted its position in Wave Life Sciences by 33.3% in the 3rd quarter. Jane Street Group LLC now owns 142,014 shares of the company's stock valued at $1,165,000 after buying an additional 35,472 shares during the period. Weiss Asset Management LP bought a new position in Wave Life Sciences in the 3rd quarter worth about $164,000. Finally, State Street Corp grew its stake in Wave Life Sciences by 2.6% in the 3rd quarter. State Street Corp now owns 2,321,248 shares of the company's stock worth $19,034,000 after acquiring an additional 57,822 shares in the last quarter. Hedge funds and other institutional investors own 89.73% of the company's stock.

Wave Life Sciences Price Performance

Wave Life Sciences stock traded down $0.58 during trading hours on Friday, reaching $12.90. The stock had a trading volume of 595,165 shares, compared to its average volume of 1,110,006. The company has a market cap of $1.97 billion, a price-to-earnings ratio of -11.62 and a beta of -1.21. The business's 50 day moving average price is $14.41 and its 200-day moving average price is $9.27. Wave Life Sciences Ltd. has a 52 week low of $3.50 and a 52 week high of $16.74.

Insider Transactions at Wave Life Sciences

In other news, insider Chris Francis sold 36,000 shares of the company's stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $16.00, for a total transaction of $576,000.00. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Paul Bolno sold 90,474 shares of the stock in a transaction that occurred on Wednesday, October 16th. The shares were sold at an average price of $15.00, for a total transaction of $1,357,110.00. Following the completion of the transaction, the chief executive officer now directly owns 268,585 shares of the company's stock, valued at $4,028,775. The trade was a 25.20 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 436,544 shares of company stock valued at $6,271,569 in the last 90 days. Insiders own 29.10% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. StockNews.com downgraded shares of Wave Life Sciences from a "hold" rating to a "sell" rating in a research note on Wednesday, November 13th. Truist Financial lifted their target price on Wave Life Sciences from $17.00 to $36.00 and gave the company a "buy" rating in a research report on Tuesday, November 12th. JPMorgan Chase & Co. increased their price target on Wave Life Sciences from $13.00 to $17.00 and gave the stock an "overweight" rating in a research report on Thursday, October 17th. Leerink Partners lifted their price objective on Wave Life Sciences from $20.00 to $22.00 and gave the company an "outperform" rating in a report on Wednesday, October 16th. Finally, Wells Fargo & Company upped their price objective on shares of Wave Life Sciences from $11.00 to $22.00 and gave the stock an "overweight" rating in a research note on Wednesday, October 16th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $22.22.

Wave Life Sciences Company Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.